Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Table 2

Comparison of mean and SE percent change in biochemical markers of bone turnover from baseline to final between the two groups. Significant differences were observed in urine NTX, osteocalcin, and BSAP.

		Placebo	Zoledronic acid	P-value
Serum creatinine (mg/dL)	𝑁	13	15	.58
	Baseline	0.969 (0.073)	0.960 (0.050)
	Final	1.008 (0.055)	0.993 (0.055)
	Mean % change	+9.8 (10)	+3.7 (2.8)
Serum calcium (mg/dL)	𝑁	13	15	.45
	Baseline	9.654 (0.12)	9.267 (0.15)
	Final	9.515 (0.11)	9.247 (0.11)
	Mean % change	−1.36 (1.1)	−0.02 (1.4)
Urine NTX Collagen cross-linked urine (nmol BCE/mmol creatinine)	𝑁	13	14	.022*
	Baseline	38.2 (4.9)	41.4 (5.3)
	Final	40.4 (4.0)	18.8 (2.3)
	Mean % change	+32 (30)	−49 (6.6)
Serum osteocalcin (ng/mL)	𝑁	13	14	.0003*
	Baseline	23.7 (1.5)	25.2 (2.5)
	Final	18.6 (1.6)	11.6 (1.4)
	Mean % change	−22.1 (3.5)	−51.6 (6.1)
Serum bone-specific alkaline phosphatase (BSAP) (mcg/L)	𝑁	13	15	.002*
	Baseline	15.5 (2.0)	14.3 (1.3)
	Final	14.9 (2.0)	8.1 (0.9)
	Mean % change	−2.0 (7.3)	−38.8 (7.5)

*Significant at level 0.05. Standard error follows mean in parentheses.